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Lung cancer remains the most incident malignancy worldwide, representing 13% of all cancers. 
It is also the leading cause of death in the world, accounting for 18.2% of global cancer-related 
deaths. The burden of lung cancer in Africa is increasing due to ageing and population growth, 
increased prevalence of risks factors such as smoking, occupational exposure, infections, 
lifestyle changes, and environmental pollutants. The efficacy of many therapeutic strategies 
has been hindered by normal tissue toxicity and treatment resistance. For many cancer patients, 
radiotherapy has been the chosen therapeutic option to minimise cancer cell spread by 
shrinking the tumour while ensuring protection of normal tissue. There is evidence that small 
molecule inhibitors can effectively target cell survival signalling pathways, but cancer cells 
manage to find molecular escape routes to either repair the damage or evade cell death. 
Combination therapy appears to be an appropriate approach to address these challenges. 
Therefore, targeting more than one component of the cell survival signalling pathways could 
potentially sensitise cancer cells to irradiation and improve the outcome of radiotherapy. 
The purpose of this study was to evaluate the role of targeting the anti-apoptotic (B-cell 
lymphoma 2 (Bcl-2)) pathway and the DNA repair (poly (ADP-ribose) polymerase 1 (PARP-
1)) pathway with specific inhibitors in modulating the radiosensitivity of a lung cancer cell line 
(A549) and an apparently normal lung cell line (L132). For this, Bcl-2 and PARP-1 were 
inhibited using ABT-737 and ABT-888, respectively.  
 
 
At a dose of 2 Gy, the typical fractional dose in conventional radiotherapy, combined inhibition 





only the A549 cells. However, at a larger radiation dose of 6 Gy (a potentially useful fractional 
dose in hypofractionated radiotherapy), inhibition of Bcl-2 and PARP-1 markedly 
radiosensitised the apparently normal (L132) and malignant (A549) cell lines, respectively.  
 
These findings suggest that use of Bcl-2 and PARP-1 inhibitors might be beneficial when 
combined with conventional radiotherapy, but not with hypofractionated radiotherapy when 
large fractional radiation doses are employed. However, validation of these results with a larger 




















Longkanker bly die wêreldwyd mees maligne maligniteit, wat 13% van alle kankers 
verteenwoordig. Dit is ook die grootste oorsaak van sterftes ter wêreld, wat verantwoordelik is 
vir 18,2% van die wêreldwye sterftes aan kanker. Die las van longkanker in Afrika neem toe 
as gevolg van veroudering en bevolkingsaanwas, verhoogde voorkoms van risikofaktore soos 
rook, blootstelling aan die werk, infeksies, lewenstylveranderinge en omgewingsbesoedeling. 
Die doeltreffendheid van baie terapeutiese strategieë word belemmer deur normale 
weefstoksisiteit en behandelingsweerstand. Vir baie kankerpasiënte was radioterapie die 
gekose terapeutiese opsie om die verspreiding van kankerselle te verminder deur die gewas te 
laat krimp, terwyl normale weefsel beskerm word. Daar is bewyse dat kleinmolekule-remmers 
effektief kan mik op die oorlewingssignale van selle, maar kankerselle slaag daarin om 
molekulêre ontsnaproetes te vind om die skade te herstel of om die seldood te voorkom. 
Kombinasie-terapie blyk 'n gepaste benadering te wees om hierdie uitdagings die hoof te bied. 
Daarom kan die fokus van meer as een komponent van die seinoorlewings seinweë moontlik 
kankerselle sensitief maak vir bestraling en die uitkoms van bestraling verbeter. 
 
Die doel van hierdie studie was om die rol van die anti-apoptotiese (B-sel limfoom 2 (Bcl-2)) 
pad en die DNA herstel (poly (ADP-ribose) polimerase 1 (PARP-1)) pad met spesifieke 
inhibeerders te evalueer. in die modulering van die radiosensitiwiteit van 'n longkanker-sellyn 
(A549) en 'n skynbaar normale longsellinie (L132). Hiervoor is Bcl-2 en PARP-1 geïnhibeer 







By 'n dosis van 2 Gy het die tipiese fraksionele dosis in konvensionele radioterapie, 
gekombineerde inhibisie van Bcl-2 en PARP-1 of inhibisie van Bcl-2 alleen gelei tot 
beduidende radiosensitisering in slegs die A549-selle. By 'n groter bestralingsdosis van 6 Gy 
('n potensieel nuttige fraksionele dosis in hipofraktioneerde radioterapie) het die inhibisie van 
Bcl-2 en PARP-1 egter die skynbaar normale (L132) en kwaadaardige (A549) onderskeidelik 
radiosensitiviseer. 
 
Hierdie bevindings dui daarop dat die gebruik van Bcl-2 en PARP-1-remmers voordelig kan 
wees as dit gekombineer word met konvensionele radioterapie, maar nie met 
hipofraktionerende radioterapie wanneer groot fraksionele bestralings dosisse gebruik word 













DELINEATIONS AND LIMITATIONS 
 
During this research, biomolecules as inhibitors of Bcl-2 (ABT-737) and PARP-1 (ABT-888) 
were used to potentially radiosensitise two lung cell lines, A549 (cancer) and L132 (apparently 
normal). The parameters that were determined using the colony formation assay included the 
innate cellular radiosensitivity and the cytotoxicity of each inhibitor alone or when combined 
with irradiation. The inhibitor-irradiation experiments were to assess the radiomodulatory 
effects of the inhibitors. Radiomodulatory effects (expressed as modifying factors in cell 
survival) were evaluated in each cell line at inhibitor equivalent concentrations for 50% cell 
kill (EC50).  
 
The main limitation of this study is that it was performed using only two lung cell lines: the 
cancer cell line, A549, and the apparently normal cell line, L132. This finding could be 
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The study done by the World Health Organization in 2015 revealed that cancer is the number 
one cause of death before the age of 70 years in 91 of 172 countries; and ranks third in an 
additional 22 countries. GLOBOCAN, a consortium that uses data from the International 
Association of Cancer Registries (IACR) to provide statistics on cancer mortality and 
prevalence,  estimates that lung cancer is the most frequent cancer and leading cause of death 
among males and the third cause among females (Bray et al., 2018). Lung cancer is also the 
leading cause of cancer death amongst men in Southern and Northern Africa, as well as being 
the fourth leading cause of death among women in Southern Africa (Dela Cruz et al., 2011). 
Data reporting of cancer epidemiology in the African continent has been limited by the lack of 
reliable registries. The incidence and mortality of lung cancer in Africa are lower compared to 
other continents due to low prevalence of smoking (10% in men and less than 2% in women) 
associated with lower life expectancy of the population (Jemal et al., 2012). An average of 10 
- 20% of non-smokers reportedly have lung cancer, with a much higher incidence in women 
than in men (Wakelee et al., 2007). Aside from tobacco smoking as the main cause, other 
contributory factors associated with the onset of lung cancer may be environmental exposure 
to radon or different chemicals, radiation, coal smoke as well as indoor emission of burning 
fuel (Jemal et al., 2010; Loomis et al., 2013). The incidence and mortality rates of this pandemic 
seem to mirror one another since most patients diagnosed with the disease eventually die from 





an estimated 1.8 million deaths, on average 18% of the global cancer mortality (Sung et al., 
2021).  
 
Conventional cancer treatment options include chemotherapy, radiotherapy, and surgery, 
depending on the type of lung cancer (small or non-small cell), the size and position of the 
cancer, the stage, and the patient’s overall health. Globally, lung cancer appears to show an 
annual mortality rate approaching that of breast and prostate cancer combined (Sung et al., 
2021); although an increasing number of lung cancer patients, akin to their breast and prostate 
counterparts, receive some form of treatment and the mentioned therapeutic options are often 
used in combination with each other.  
 
Surgery alone might not yield the required treatment outcome, as the removal of a primary 
tumour may miss tissue that has been invaded by tumour cells, and radiotherapy is often used 
to treat the tumour bed. In cases of advanced tumour stages, systemic treatment by means of 
chemotherapy is employed. These combinations often lead to severe side-effects from which 
patients may not recover. 
 
Previous studies have been focused on the use of inhibitors to target pathways like those of 
PI3K/mTOR and EGFR to radiosensitise breast, prostate, and cervical cancer cell lines 
(Hamunyela et al., 2015; Maleka et al., 2015; 2019; Hamid et al., 2016; Hamid, 2019). These 
signaling pathways are involved in cancer proliferation and migration, and prevent cancer cell 





cervical cancer cells, high level of toxicity in apparently normal lung cells and breast and 
prostate cancer cells, and radioprotection in normal prostate cells (Hamunyela et al., 2015; 
Maleka et al., 2015; Hamid, 2019). There is, therefore, the need to identify new and more 
effective treatment approaches that could improve prognosis in lung cancer patients. The 
current study aimed to evaluate small molecule inhibitors (ABT737 and ABT888) of key 
survival signalling pathways (Bcl-2 and PARP-1) for their capacity to preferentially enhance 






1.2. Rationale and Problem Statement 
 
Lung cancer is a regular form of malignancy accounting for thousands of deaths in Western 
and Eastern countries (Ferlay et al., 2007; 2010; 2013). At the beginning of the 20th century, 
lung cancer was seen as a rare disease but rose dramatically a decade later due to an increase 
in smoking and environmental and genetic factors. Continuous exposure to these factors may 
lead to genetic mutations which disrupt protein synthesis. The main genes responsible for the 
development of lung cancer are B-cell lymphoma-2 (Bcl-2) and tumour protein (EC :2.7. 1.37) 
(p53) for small cell lung cancer (SCLC), and epidermal growth factor receptor (EGFR), ataxia-
telangiectasia mutant (ATM), Kirsten rat sarcoma virus (KRAS), and cyclin-dependent kinase 
inhibitor 2A (p16) for non-small cell lung cancer (NSCLC) (Cagle et al., 2013; Lindeman et 
al., 2013; 2018). Mutation of these genes leads to the formation of unusual proteins causing 
abnormal molecular or biological processes that results in the development of cancer cells 
(Hassanpour and Dehghani, 2017).  
 
Cancer treatment aims to destroy cancer cells without killing the normal cells. The preferred 
treatments are surgery, chemotherapy, and radiotherapy which can be used either alone or in 
combination with other therapies (Wild-Bode et al., 2001; Zappa and Moussa, 2016; Huang et 
al., 2017) 
 
Radiotherapy is commonly used for all types of lung cancer. However, patients often 





favorably (Torres et al., 2015). To partially address these clinical challenges, it is necessary to 
identify biomolecules that would preferentially sensitise cancer cells to the effects of radiation. 
This could form the basis for the development of novel clinical strategies that may be vital in 
improving the outcome of lung cancer therapy.  
 
Specific biomolecules appear to be a potential alternative to sensitise cancer cells to irradiation 
while protecting critical tissues. Small molecules, such as ABT-263, ABT-737, and ABT-888, 
are used in targeted therapy to locate key specific genes and/or proteins involved in cellular 
pathways that control cell survival. Programmed cell death (apoptosis) has become an attractive 
molecular process for new cancer therapy (Chen et al., 2005). Similarly, the perturbing DNA 
repair via inhibition of key components of the PARP-1 pathway shows potential for selectively 
sensitising cancer cells to radiation insult (Donawho et al., 2007), and could serve as a viable 







1.3. Research Question 
 
Does the use of biological inhibitors of pro-survival signalling pathways preferentially enhance 









It is postulated that in vitro treatment of cancer cells with mammalian proteins B-cell 
lymphoma 2 (Bcl-2) and poly (ADP-ribose) polymerase 1 (PARP-1) signalling pathway 







1.5. Aims and Objectives 
 
The purpose of this study was to assess the effect of targeting Bcl-2 and PARP-1, using small 
molecule inhibitors, on the radiosensitivity of normal and cancer cells of the human lung in 
vitro. The objectives towards achieving the goal are as follows: 
1. To determine the intrinsic radiosensitivity of two lung cell lines (1 normal; 1 cancer).   
2. To assess the effect of the Bcl-2 and PARP-1 inhibitors, administered singly or in 







1.6. Literature Review 
 
1.6.1. Cancer  
 
Cancer is a somatic disease characterised by uncontrolled cell proliferation and disruption of 
programmed cell death. Hanahan and Weinberg published a review attempting to organise the 
immense complexity of cancer biology into six major hallmarks (Hanahan and Weinberg, 
2000). This study explained that cancer cells possess the ability to grow independently using 
different signalling pathways. A key characteristic of cancer cells is their ability to disrupt cell 
death mechanisms and replicate continuously (Hanahan and Weinberg, 2000; 2011); and 
cancers were suggested to display the following characteristics: self-sufficiency in growth 
signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis. The lack of specific growth signals 
and non-specific receptors justifies the complexity of the control of tumour proliferation and 
allows these cells to be independent from the external factors. 
 
The vascularisation of tumour and, thus, enhanced nutrient supply contributes to the initiation, 
autonomy, and development of new cancer blood vessels (Hanahan and Weinberg, 2000; 
2011). Tumour vascularisation is an attractive target for therapy since the blood vessels are 





disrupting agents have gained popularity as antitumour drugs (Hinnen and Eskens, 2007; Chen 
et al., 2012; Lei et al., 2018).  
 
Radiotherapy is an essential component in the treatment of cancers for both curative and 
palliative intervention, with as many as 40% cured by radiotherapy alone, compared to 11% 
cured by chemotherapy alone (Atun et al., 2015). Despite the great contributions of 
radiotherapy towards cancer management, major clinical limitations are still observed during 
or after treatment. Tumour resistance to ionising radiation, the protection or damage of critical 
tissues, the determination of tumour control dose or toxicity dose are clinical obstacles 
undermining the effectiveness of radiotherapy (Buchholz, 2009). Efforts were initially focused 
on conventional therapies to tackle these challenges, but chemotherapy involves very toxic 
drugs that affect both cancer and normal cells by causing infections and immune suppression. 
Surgery is invasive and characterised with a high morbidity rate; and radiotherapy is cytotoxic, 
destroys normal cells and may lead to radioresistance.  
 
It is important, then, to investigate novel therapies that target different proteins to tackle the 
aforementioned clinical challenges. The objective of this study, therefore, was to use targeted 
therapeutic agents to inhibit survival signalling markers, such as Bcl-2 and PARP-1, in two 
human lung cell lines (normal:  L132; cancer: A549) in combination with radiotherapy, to 







1.6.2. Lung Cancer  
 
The lungs are the most important organs of respiration, located on either side of mediastinum, 
with functions to transport oxygen in the body and release carbon dioxide from the body. In 
2020, new cases of lung cancer totalled 235 760 (119 100 in men and 116 660 in women), and 
deaths from lung cancer totalled 131 880 (69 410 in men and 62 470 in women). Lung cancer 
is subdivided into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC) (Sung et al., 2021). NSCLC represents more than 80% of lung cancers, whilst SCLC 
covers less than 20%. NSCLC is composed of adenocarcinoma, squamous cell cancer, and 
large cell carcinoma. Lung cancer has the characteristics of being heterogeneous, highly 
aggressive, and is often clinically detected very late (Lemjabbar-Alaoui et al., 2015). These 
factors lead to poor patient response to treatment.  
 




The use of surgery to treat cancer consists of the removal of the tumour and surrounding tissues 
during an operation. Lung cancer surgery is complex with serious consequences and requires 
a highly experienced surgeon. Curative cancer surgery has long been considered as sole 
therapeutic modality to remove localised tumours, but several factors such as tumour stage, 





lymphogenic metastatic and surgical complications selectively influence and affect the success 
of surgery (Kappas and Roukos, 2002). According to the American Cancer Society, surgery 
remains the first treatment of choice for patients with early stage locoregional tumours, but not 
preferred for distant metastasis. Surgery has been reported to cause local and/or systemic 
inflammation, promote cancer signalling pathways, and induce postoperative cancer recurrence 
(Hiller et al., 2018). Nevertheless, 60% of patients are treated with surgery, offsetting the 
postoperative deleterious effects of alternative novel therapies that combine surgery with 




Chemotherapy makes use of drugs to block cell proliferation (cell mitosis) or to inhibit DNA 
repair, and its use usually depends on the stage/type of cancer, overall health of the patient, and 
the location of the cancer (Rajman et al., 2018). It is considered a systemic treatment, affecting 
the entire body, and aims to reduce the total number of cancer cells in the body, lower the 
likelihood of cancer spreading, and, in special cases, shrink the tumour size to allow a more 
effective therapy to be applied concomitantly. The benefits of chemotherapy in the relief of 
cancer symptoms, minimisation of cancer recurrence, and increase in the survival rate of 
patients, aside, chemotherapeutics have shortcomings in the damage of normal tissues due to 
cumulative cytotoxicity caused by prolonged drug treatment and in the management or control 
of metastatic tumours in both SCLC and NSCLC. Because SCLC is rarely localised at 





chemotherapy while 18% only of patients with NSCLC undergo surgery and 68% of NSCLC 
are treated either with chemotherapy or radiotherapy (Bunn Jr and Kelly, 1998; Zarogoulidis 
et al., 2013; Horn et al., 2018). Although quality of life may be improved the side-effects of 
the chemotherapeutic agents have led researchers to investigate alternative treatment 
modalities, such as combined therapeutic methods, to address these risks and further improve 




Radiotherapy is the treatment of cancer using beams of high energy rays, such as X-rays. The 
form of energy used in cancer therapy is known as ionising radiation. This form of energy is 
produced from natural or artificial sources and has high enough energy to break chemical bonds 
and cause damage to living tissue. Radiation may affect healthy cells as well as cancer cells. 
Specific side-effects depend on factors such as the area receiving treatment, the tumour cells, 
the person’s overall health, and the radiation dose/type. 
 
The two main types of radiations are: (1) sparsely ionising radiation (or low linear energy 
transfer (LET) radiation), for example, X-rays or gamma rays; and (2) densely ionising 
radiation (or high LET radiation), such as neutrons or alpha particles. Low LET particles act 
on biological tissue via an “indirect effect”. This process is observed when sparsely ionising 





cells. When high LET ionising radiation causes direct injury in biological tissue, a “direct 
effect” is said to have occurred.  
 
DNA is referred to as the blueprint of life and contains all the information required for a cell 
to grow, develop, survive and reproduce, and represents a critical target of radiation (Vignard 
et al., 2013). Therefore, it is sensible to ensure that the genetic information coded in DNA can 
always be recovered, even from a single strand. The preservation of the genetic information, in 
its original state, is dependent not only on the accuracy of its copying during DNA replication, 
but also on the timely repair of any damage which may compromise the integrity of the DNA 
molecule, and/or may change its building blocks, or their arrangement, in any manner.  
 
Ionising radiation may cause damage to single-strand DNA as well as double-strand DNA. 
Radiotherapy achieves its therapeutic effect by inducing damage and eventual cell death if the 
damage is not reversed (Baskar et al., 2008). Radiotherapy can cause reversible or repairable 
damage, called “sublethal damage”, when low doses of ionising radiation are used; but when 
exposed to high doses, “lethal damage” is induced and can lead to cell death.  
 
Tumour resistance to ionising radiation may result from the ability of cancer cells to withstand 
radiation insult by using DNA repair mechanisms or evasion of programmed cell death 
(apoptosis) which may be achieved via escape molecular signalling pathways. Typical 
examples of DNA repair and pro-survival pathways are those of PARP-1 and Bcl-2, 





chemotherapeutic drugs or as a neo-adjuvant with surgery by causing reduction of the tumour 
size. However, this intervention is limited by tumour radioresistance, systemic tumour 
progression and local or distant metastasis (Wild-Bode et al., 2001; Huang et al., 2017) 
 
1.6.4. Contemporary Cancer Therapies 
 
1.6.4.1. Targeted Therapy 
 
Targeted therapy is a cancer treatment that uses drugs to locate specific genes and proteins 
involved in cancer proliferation and survival (Gerber, 2008; Attia et al., 2019). It may impact 
on the environment helping the cancer growth or it may target cells related to cancer 
regeneration. Targeted therapy may block or turn off signals involved in the cancer 
proliferation or spread, may prevent the cancer cells from living longer than normal or may 
destroy them (Attia et al., 2019). The direct approach targeted therapy focuses on the 
identification of tumour antigens to alter their signaling pathways either by monoclonal 
antibodies or by small molecule drugs that interfere with these target proteins. The indirect 
approaches targets tumour antigens expressed on the cell surface of the cancer cells, using 
tumour specific monoclonal antibodies or peptide ligands binding to receptors that exist in the 
tumour cells. Apart from active targeted therapy, a passive targeted mechanism is also observed 
where tumours are targeted by macromolecules using the enhanced permeability and retention 
effects associated with hyperpermeable angiogenic tumour vasculature due to the absence of 





1.6.4.1.1. Antibody-Targeted Therapy 
 
The technique to produce monoclonal antibodies (Mabs) was developed in 1975 by Kohler and 
Milstein and this technology made a great contribution to the treatment of several different 
malignancies (Harris, 2004). Monoclonal antibodies are man-made proteins that act like human 
antibodies and have a specific target on a cancer cell where they bind and attack the tumour 
cell. Some examples of Mabs as targeted therapy are the use of trastuzumab for HER-2-positive 
breast cancer, cetuximab for EGFR-positive colorectal lymphomas, and rituximab for B-cell 
surface protein CD20 (Keller et al., 2007). 
 
1.6.4.1.2. Small Molecule Targeted Therapy 
 
The endless knowledge surrounding molecular events that govern the signalling pathways of 
different types of cancer has led to the development of novel agents. The phosphorylation and 
dephosphorylation of proteins are important posttranslational modification processes during 
protein synthesis, playing crucial roles in signal transduction and switching of enzymatic 
activity (Sacco et al, 2012). Anti-apoptotic behaviour, unrestricted proliferation, and 
angiogenesis are consequences of aberrant phosphorylation in cancer (Cicenas et al., 2006; 
Maatta et al., 2006; Troussard et al., 2006). Therefore, small molecule inhibitors of protein 
kinases such as plasma membrane-associated protein tyrosine kinases have emerged as 
indispensable in targeted therapy. Some examples of tyrosine kinase inhibitors are imatinib, 





encoding for abnormal proteins, leading to human cancer; Gefitinib or erlotinib, a selective oral 
epidermal growth factor receptor tyrosine kinase inhibitor which is involved in the disruption 
of EGFR kinase activity by binding the ATP pocket within the catalytic domain, decreasing 
mitogen-activated protein kinase activity, increasing apoptosis and increasing the level of 
cyclin dependent kinase p27 responsible for G1 cell cycle arrest. Figure 1.1 Overview of small 





Figure 1.1: Overview of various targeted inhibitors in the market. Small molecules inhibitors target key genes 
and signaling pathways by reversing the biological behavior of the tumour cells, so as inhibiting cancer 








1.6.4.1.3. Ligand-Based Targeted Therapy 
 
Most cancer cells share common features with their counterpart normal host cells from which 
they originated such as a lack of unique molecular targets that would differentiate them from 
normal cells. Therefore, increasing the therapeutic dose of the tumour cells may lead to the 
damage of the normal tissue. Ligand targeted therapy offers selective toxicity by increasing the 
amount of the drug reaching the tumour cells. This technique of tumour targeting, not only 
limits normal tissue toxicity, but also overcomes obstacles such as elevated interstitial fluid 
pressure in tumours, drug resistance, and nonspecific drug delivery that are often encountered 
in chemotherapy (Wu et al., 2006; Li et al., 2016). An example of ligand-based targeted therapy 
is the nanoparticle-mediated targeted drug delivery system which involves a chemotherapeutic 
agent, a delivery vehicle targeting the tumour, and a surface ligand that mediates the delivery 
vehicle’s interaction with the tumour at high specificity and high concentration. 
 
Tumour drug resistance and normal cell toxicities are hallmarks of chemotherapy. The 
development and discovery of targeted therapy was to allow greater tumour specificity and less 
toxicity of the normal cells (Li et al., 2016). Recently, some attempts have been made to address 
these therapeutic challenges such as monoclonal antibodies targeted therapy, ligand based 
targeted therapy and small molecule inhibitors targeted therapy by locating tumour specific 
receptors, blocking tumour proliferation, and decreasing the level of damage to the normal 
tissue. However, no matter the promising clinical results from the agents highlighted there is 





that most solid tumors are caused by various genetic mutations and the inhibition of a single 
molecular pathway may not result in a significant therapeutic outcome (Wu et al., 2006; Li et 
al., 2016). In addition to this, the acquired resistance to protein inhibitors by tumours that 
initially respond positively is due to mutations in the binding sites of the inhibitors, which lead 
to the failure of agents to generate any detectable response to subsequent treatment. A classic 
example is the oncogenic mutation in the case of EGFR kinase where methionine is substituted 
with threonine at amino acid position 790 (T790 M mutations) of the cancer cells, providing a 
tumour growth advantage alongside a drug-resistant variant of the targeted protein kinase (Pao 
et al., 2005; Kobayashi et al., 2005). Therefore, the ongoing obligation to develop therapy that 
will target many tumour pathways and reduce normal tissue toxicity, is urgent. The 
combination of targeted therapy with another therapeutic mode, such as radiotherapy, was 
considered as a novel strategy to respond to this challenge. 
 
1.6.4.2. Combination Therapy 
 
Combined drug therapy is a mode of treatment that consists of increasing the action of one 
molecule by either increasing its penetration or disrupting its binding activity (Reece et al., 
2007, Chanan-Khan et al., 2010). The rationale of this mode of treatment is to use drugs that 
work by different mechanisms, thereby decreasing the onset of tumour cell resistance. 
Combination cancer therapies aim to improve the probability and magnitude of therapeutic 
responses and reduce the likelihood of acquired resistance to single therapy. Multiple drugs 





improve the therapeutic efficacy by targeting the same molecular pathway (Lee and Nan, 2012; 
Burris, 2013).  
 
Depending on the type of cancer, the effective approach may be a combination of surgery, 
radiotherapy, chemotherapy, or other therapy, such as targeted therapy. Radiotherapy may be 
used prior to another therapy to shrink a tumour to optimise the existing treatment (called 
neoadjuvant therapy) or may be given after to kill any remaining cancer cells (called adjuvant 
therapy). 
 
1.6.5. Cell Signalling Pathways of Interest 
 
An evaluation of the effect of inhibiting cell signalling pathways in cellular radiosensitivity 
might have a beneficial impact on the treatment of lung cancer patients. For this, the cell death 
and DNA repair pathways, specifically those of Bcl-2 and PARP-1, are of particular interest.   
 
1.6.5.1. The Programmed Cell Death (Apoptosis) Pathway  
 
The term apoptosis (a-po-toe-sis) was first used in a paper by Kerr et al. (1972) to explain a 
morphologically different type of cell death and a non-inflammatory biochemical mechanism. 
This phenomenon is considered a vital component of various processes such as normal cell 
turnover, normal development and functioning of the immune system, hormone-dependent 





to Kerr, dysfunctional apoptosis (either too little or too much) is a problem in many human 
conditions, including neurodegenerative diseases, ischaemic damage, autoimmune disorders, 
and most types of cancers. Much research has been focused on the elucidation and analysis of 
the cell cycle and signalling pathways that modulate cell cycle arrest and apoptosis because of 
their tremendous therapeutic potential in the modulation of life or death of a cell (Pucci et al., 
2000; Elmore, 2007; Brunelle and Letai, 2009; Dorn, 2012; Carneiro and El-Deiry, 2020; 
Shahar and Larisch, 2020). Unregulated cell proliferation may lead to pathologic insult, if it is 
not countered by an appropriate apoptotic response (Pucci et al., 2000). During development 
and ageing, apoptosis plays a role in homeostasis by maintaining cell populations and in 
defense mechanisms, such as in immune reactions or when cells are damaged. The main 
morphological changes following apoptosis, as identified by light and electron microscopy, 
are: plasma membrane blebbing, cell shrinkage, nuclear fragmentation, pyknosis as a result of 
chromatin condensation, and cell surface molecule changes to ensure that apoptotic bodies are 
recognised and engulfed by neighbouring cells or phagocytes in in vivo systems (Kerr et al., 
1972). The tightly regulated process of phagocytosis ensures either little or no inflammation. 







Figure 1.2: Morphological features of cell death (Ziegler and Groscurth, 2004): (A) - Normal cell morphology; 
(B) and (C) - Blebbing of the cell membrane; and (D) Chromatin condensation, fragmentation of the nucleus, and 
formation of apoptotic bodies. 
 
There are two main apoptotic pathways, namely, the extrinsic or death receptor pathway and 
the intrinsic or mitochondrial pathway. The extrinsic signalling pathway involves 
transmembrane receptor-mediated interactions by activating death receptors which are 
members of the tumour necrosis factor (TNF) receptor genes superfamily (Locksley et al., 
2001; Giussani et al., 2014). These members have a cytoplasmic domain of about 80 amino 
acids, named the “death domain”, and share similar cysteine-rich extracellular regions 
(Ashkenazi and Dixit, 1998). The death domain is responsible for carrying death signals from 
the cell surface to the intracellular signalling pathways. The extrinsic phase of apoptosis is 
characterised with FasL/FasR and TNF-α/TNFRI models, where clustering of receptors and 





inducing complex (DISC), formation of procaspase-8 and caspase 8 to trigger apoptosis 
(Ashkenazi and Dixit, 1998; Giussani et al., 2014). 
 
The intrinsic pathway involves an array of non-receptor mediated stimuli that produce 
intracellular signals acting directly on targets within the cell and are initiated by mitochondria. 
The control of these mitochondrial events happens through members of the B-cell lymphoma 
2 (Bcl-2) family of proteins (Cory and Adams, 2002; Shahar and Larisch, 2020), where the 
tumour suppressor protein p53 plays a critical function in the regulation of the Bcl-2 family of 
proteins. The extrinsic and intrinsic apoptotic pathways are depictured in Figure 1.3. 
 
 
Figure 1.3: Schematic representation of the extrinsic and intrinsic apoptosis pathways with pro-apoptotic 






The mechanisms of apoptosis are highly complex and sophisticated, displaying an energy-
dependent cascade of molecular reactions, as shown in Figure 1.4, which may take a mere 15 
minutes and is, therefore, difficult to detect in tissue sections (Martin, 1993). A family of 
mammalian proteins B-cell lymphoma 2 (Bcl-2) may promote or inhibit cell death by 
regulating the permeabilisation of the mitochondria outer membrane. Bcl-2 anti-apoptotic 
proteins are represented by Bcl-2 itself, as well as B-cell lymphoma-extra-large (Bcl-xL), and 
B-cell leukaemia/lymphoma-w (Bcl-W) and myeloid cell leukaemia-1 (Mcl-1), and pro-
apoptotic proteins are composed by Bcl-2-like protein 4 (Bax) and Bcl-2 antagonist killer 1 
(Bak) (Brunelle and Letai, 2009), as shown in Figure 1.3. It appears that the main mechanism 
of action of the Bcl-2 family protein is primarily the regulation of cytochrome C release via 
alteration of the mitochondrial membrane permeability (Zha et al., 1996). This leads to the 
formation of the ternary complex of cytochrome C, the adapter protein Apaf-1, and the initiator 
caspase 9, followed by the sequential activation of effector caspases causing endonuclease 
action resulting in cellular disintegration. Researchers believe that the lack of apoptosis was 
suggested to be implicated in the pathogenesis of a variety of human diseases including cancer 
and many other chronic diseases (Thompson, 1995; Reed, 2000; Liu et al., 2004; Wong, 2011). 
The dysregulation of programmed cell death may be represented by overexpression of Bcl-2 in 
many cancers and contributes to tumour progression and resistance to therapy. Preferentially, 
silencing Bcl-2 in tumour cells with specific small molecule inhibitors should render them more 







1.6.5.2. The DNA Repair Pathway 
 
An alternative strategy to effectively improve ionising radiation at lower doses, may be the use 
of radiosensitisers to target recognition and repair of deoxyribonucleic acid (DNA) damage. 
Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that use nicotinamide 
adenine dinucleotide (NAD+) as a substrate to polymerize onto their cellular targets. PARP-1 
and PARP-2 isozymes are activated by DNA damage and seem to participate in single-strand 
DNA break repair by activating the repair protein, X-ray repair cross-complementing protein 
1 (XRCC1), base-excision repair, and double-strand DNA break repair, through the influence 
of both homologous recombination and non-homologous recombination (Veuger et al., 2003), 
as shown in Figure 1.4. Unlike PARP-2, PARP-1 is the most active protein, responsible for 
about 90% of cellular PARP formation, and is the highly conserved protein during evolution 
(Schreiber et al., 2002), and targeting the latter could prove beneficial in cancer therapy. In 
fact, small molecule inhibitors of PARP-1 have shown significant promise, and third generation 
PARP inhibitors have been investigated in clinical trials (Lord and Ashworth, 2008; Weaver 
and Yang, 2013). 
 
The potential use of PARP inhibitors requires an in-depth understanding of their mechanisms 
of actions and the effects of modifying factors on PARP inhibitor susceptibility. PARP protein 
is involved in many cellular processes which includes single-strand break repair (SSBR) and 
double-strand break repair (DSBR). Compared to single-strand breaks (SSBs), DNA double-





sufficient to trigger cell death (Langelier et al., 2018). Therefore, they represent the most lethal 
of DNA lesions, eliciting the majority of the cytotoxic effects caused by ionising radiation and 
certain chemotherapeutic agents. It is stated that healthy or normal cells have minor amounts 
of DNA damages and possess full DNA repair capacity than cancer cells which have elevated 
DSBs due to oncogene-induced replication stress and defects in DNA damage response 
mechanisms. Hence, hyperproliferating cancer cells depend on DSBR for their survival, and 
this remains a major cause of radioresistance or cancer recurrence. Knowing the fact that DNA 
damage response (DDR) defects may predispose individuals to developing cancer, this same 
vulnerability can be exploited to kill tumour cells by targeting the DSB repair mechanism of 
cancer cells (Bouwman and Jonkers, 2012; O’Connor, 2015). Lung cancer is the leading cause 
of cancer death worldwide and a potential target of PARP inhibitor therapy. The use of PARP 
inhibitors to target more than one of the genes promoting cancer cell survival has proved their 
importance in clinical settings. Recent studies have been reported targeting specific cancer cells 
deficient in genes such as PARP-1 genes, ATM genes, and mostly BRCA1 or BRCA2 genes, 
using PARP inhibitors in order to improve the outcome of conventional treatment in clinics 
(McCabe et al., 2006; Murai et al., 2012; Kantidze et al., 2018; Motegi et al., 2019). This is a 
concept called “Synthetic lethality”, which asserts that not only unrepaired SSBs may lead to 
potentially lethal damages and become a threat to normal tissue, but that combining PARP 
inhibitors with others agents would target multiple nodes in DNA damage responses and 







Figure 1.4: The multiple roles of PARP-1 (Agarwal et al., 2009).  Following DNA damage, PARP-1 may play 





















2. Materials and Methods 
 
2.1. Study Location and Ethics Consideration 
 
This research as well as all the laboratory experiments were carried out in the Division of 
Radiobiology, in the Faculty of Medicine and Health Sciences (FMHS), at the University of 
Stellenbosch. No ethics approval was required since only established cell lines were used.  
 
2.2. Cell Lines and Culture Maintenance  
 
To conduct this study, two human lung cell lines (normal: L132; cancer: A549) were used. 
Cells routinely stored in liquid nitrogen (-196°C) were retrieved and cultured in their respective 




The human normal lung epithelial cell line, L132 (ATCC® Number: CCL-5™), is a p53 wild-
type cell line. It was a gift from Dr T. Robson (University of Ulster, UK). L132 was used to 
represent normal tissue. The cells were routinely grown as monolayers in 25- or 75-cm2 tissue 
culture flasks in Roswell Park Memorial Institute (RPMI-1640) medium (Sigma-Aldrich, USA, 
cat # R8758) supplemented with 10% foetal bovine serum (HyClone, UK, cat #SV30160.03) 





37°C in a humidified atmosphere (95% air, 5% CO2). Cells were used for experiments upon 




A549 is an adenocarcinoma human alveolar basal cell line collected from a 58-year old 
Caucasian male. It has an epithelial-like structure and is often utilised for the study of lung 
cancer. It is hypotriploid and grows as a monolayer in RPMI-1640 medium (Sigma-Aldrich, 
USA, cat # R8758), mixed with 10% heat-inactivated foetal bovine serum (HyClone, UK, cat 
#SV30160.03), penicillin (100 U/ml) and streptomycin (100 µg/ml) (Lonza, Belgium cat # 
DE17-602E). The cells were routinely cultured at 37°C in a humidified atmosphere (95% air, 
5% CO2). The A549 cell line has been used extensively in cancer proliferation studies and has 
served as a testing ground for novel drug development (Giard et al., 1973). The cell line was 
purchased from Cellonex (Johannesburg, South Africa, cat # CA54-C) and passages ranging 
from 25-65, at 70-80% confluence, were used in this study. 
 
2.3. Target Inhibitors  
 
Two inhibitors, ABT-737 and ABT-888, were used to target vital cell survival proteins, namely 







2.3.1. ABT-737  
 
ABT-737 (C42H45ClN6O5S2; MW = 813.4 g; cat # 11501, Biocom Africa, South Africa) is a 
small molecule drug that inhibits two members of the Bcl-2 family, namely Bcl-2 and Bcl-xL. 
The chemical structure of ABT-737 is shown in Figure 2.1. ABT-737 is not orally bioavailable 
which can limit its administration, especially in the case of multiple fractionated doses or as an 
adjuvant. In this study, 3.1 mM stock solution of ABT737, dissolved in DMSO, was stored at 
-20ºC until used.  
 
Figure 2.1: Chemical structure of ABT-737. 
 
 
2.3.2. ABT-888  
 
ABT-888 (C13H16N4O; MW = 244.29 g; gift from the Drug Synthesis and Chemistry Division 
(National Cancer Institute, USA)) inhibits the PARP activity in cells. ABT-888 inhibits the 
DNA repair mechanism by blocking the action of the polymerase enzyme PARP-1 and reduces 
clonogenic survival (Bouchard et al., 2003). This makes ABT-888 an attractive drug in the 





2016). Figure 2.2 shows the chemical structure of ABT-888.  The stock solution consisted of 
2.1 nM of ABT888, dissolved in DMSO, and was stored at -20ºC until used for experiments. 
 
 
Figure 2.2: Chemical structure of ABT-888. 
 
 
2.4. Irradiation of Cell Cultures  
 
Cells were irradiated to doses ranging from 0 to 10 Gy at a dose rate of 1.0 Gy/min, using a 
Precision MultiRad 160 X-ray irradiator (Precision X-Ray Inc., Branford, CT, USA) at the 
Division of Radiobiology (Faculty of Medicine and Health Sciences, Stellenbosch University). 
The irradiation of cells was performed at a source-to-sample distance of 65 cm at room 
temperature (22°C), with 10 ml of culture medium in the 25-cm2 flasks serving as build-up 







2.5. Clonogenic Cell Survival Assay 
 
The colony formation assay was used to assess cell survival following irradiation and specific 
inhibitor treatment. Briefly, 70-80% confluent stock cultures were washed with sterile 
phosphate buffered saline (PBS) (Lonza, Belgium, cat # 17-512F), trypsinised, and the cells 
counted using a haemocytometer. Cells were then seeded in triplicate per experiment in 25-
cm2 tissue culture flasks at 100 - 10 000 cells per flask (for X-ray exposure, depending on the 
radiation absorbed dose: 0 - 10 Gy) and from 200 to 6000 cells per flask (for inhibitor treatment, 
depending on inhibitor concentration: 0 - 10000 nM). After 4-5 hours of incubation at 37°C for 
the cells to attach, the cultures were subjected to the respective radiation doses or inhibitor 
concentrations. The cell cultures were exposed to inhibitors for the entire duration of 
experiments. The cultures were then incubated for 7 or 14 days (depending on cell line) for 
colony formation. The normal cell line were incubated for 14 days, while its counterpart cancer 
cell line was incubated for 7 days. The growth media were decanted and the colonies washed 
with PBS, fixed with a mixture of glacial acetic acid, methanol, and deionized water (v:v:v:) 
for 10 minutes, stained with 0.01% Amido Black in fixative for 30 minutes. The stained 
colonies were then washed in tap water and left to dry. The colonies were counted using a 
stereoscopic microscope (Nikon, Japan; Model #: SMZ-1B). The average of the surviving 
fractions (SF) for three independent experiments were determined, following each respective 
radiation dose and inhibitor concentration, as follows: 
 






where ncol(u) and ncol(D) (or ncol(C)) are the number of colonies scored in non-irradiated (or 
untreated with inhibitor) (control) samples and those irradiated to dose D (or treated with 
inhibitor at concentration C), respectively. ncell(D) and ncell(u) are the number of cells seeded 
in irradiated (or treated with inhibitor at concentration C) and control cultures, respectively. 
 
To obtain cell survival curves for radiation experiments, the surviving fractions for doses D (in 
Gy) were fitted to the linear-quadratic model: 
 
SF= exp[-αD-βD2]     (Eq. 2.2), 
 
where α and β are the coefficients of the linear and quadratic cell components of cell kill. From 
these curves, the radiosensitivity of the cell lines was determined and expressed in terms of the 
surviving fractions at 2 Gy (SF2: for low fraction dose response) and 6 Gy (SF6: for large 
fraction dose response), and mean inactivation dose which is the area under the cell survival 
curve (𝐷ഥ: for integrative low-high dose response).   
 
Inhibitor cytotoxicity was depicted by plotting the surviving fractions (SF) against the 
logarithms of inhibitor concentrations (Lc) and fitting the data to a a 4-parameter logistic 
equation of the form:  
 
 𝑆𝐹 = 𝐵 +
𝑇−𝐵
{1−10[(𝑙𝑜𝑔𝐸𝐶50−𝐿𝑐)𝐻𝑆}






where B and T are the minimum and maximum of the sigmoidal curve, respectively, EC50 is 
the equivalent concentration for 50% cell kill, and HS is the steepest slope of the curve.  
 
2.6. Effect of Bcl-2 and PARP-1 Inhibitors on Radiation Response 
 
To evaluate the effect of inhibiting Bcl-2 and PARP-1 on radiosensitivity, the colony assay 
was performed in irradiated cell cultures that were pre-treated with ABT-737 and ABT-888, 
respectively.  For this, pre-prepared cultures (seeded at 300 to 10000 cells per 25-cm2 flask) 
were treated with inhibitors, singly or combined, at the EC50 estimated from the toxicity 
experiments (Eq. 2.3) 30 min prior to irradiation (at 2 and 6 Gy). The cells were then incubated 
for colony formation (7 days for A549; 14 days for L132), and surviving fractions were 
determined as described under Section 2.5. Inhibitors were left in cell culture media for the 
entire duration of experiments. The radiomodulatory effect of the inhibitors was expressed in 
terms of a survival modifying factor (MF) for small and large fractional doses, defined as: 
 
MF2 = SF(2 Gy)/{SF(EC50+ 2 Gy)} or MF6 = SF(6 Gy)/{SF(EC50+ 6 Gy)}  (2.4). 
 
The criteria for inhibition, no effect, and enhancement of radiosensitivity by inhibitors were as 








2.7. Data Analysis 
 
Data were analysed using the GraphPad Prism software (GraphPad Software, San Diego, CA, 
USA). Data were presented as the mean (± SEM) from three independent experiments. For 
each experiment and data point, 3 replicates were assessed. Where necessary, errors were 
determined using appropriate error propagation formulae. For the comparison of two data sets, 
the unpaired two-sided t-test was used. A P < 0.05 indicated a statistically significant difference 



















3.1. Intrinsic Radiosensitivity 
The response of the human lung cell lines (normal: L132; cancer: A549) used in this study to 
exposure to ionising radiation was determined using the colony formation assay (14 days for 
the normal cell line; 7 days for the cancer cell line). The respective cell survival curves, as 
obtained by fitting survival data to the linear-quadratic model (Eq. 2.2) are shown in Figure 
3.1. On average, the normal cell line is more radiosensitive and exhibits a steeper survival curve 
than its cancer counterpart. This is also apparent from the radiobiological parameters presented 
in Table 3.1.  
 
Figure 3.1. Clonogenic cell survival curves for 2 human lung cell lines (normal: L132; cancer: A549) after X-ray 
irradiation. Symbols represent the mean surviving fraction ± SEM from three independent experiments. Survival 






However, the value of SF2 and 𝐷ഥ as predictors of differential radiosensitivity between L132 
and A549 is minimal as the differences in these parameters did not reach statistical significance. 
A comparison of the SF2 and 𝐷ഥ values of the cell lines yielded P-values of 0.7158 and 0.1756, 
respectively. The normal cell line is significantly more radiosensitive at large fractional 
radiation doses of the order of 6 Gy than its malignant counterpart (P = 0.0011). The α/β ratio 
which is routinely used in the clinic as a tool for gauging the radiation response of tissue also 
emerged as a sensitive predictor of radiosensitivity, with L132 being approximately 40% more 
radiosensitive than A549 (Table 3.1).  
 
Table 3.1. Summary of radiobiological parameters for the L132 and A549 cell lines. SF2 and SF6 denote the 
surviving fraction at 2 and 6 Gy, respectively. α and β are the linear and quadratic coefficients of cell inactivation, 
respectively. 𝐷ഥ denotes the mean inactivation dose (area under the cell survival curve). Data are presented as the 
mean ± SEM from 3 independent experiments. 
#Errors calculated from a standard error propagation formula. 
 
3.2. Cytotoxicity of ABT-737 in L132 and A549 Cells 
 
Inhibition of Bcl-2 with ABT-737 yielded a concentration-dependent cell kill in the L132 and 
A549 cell lines (Figure 3.2). At toxic concentrations of the inhibitor, the normal cell line (L132) 
shows a much steeper cytotoxic response than the cancer cell line (A549), indicating that small 
increments in ABT-737 result in more cell kill in the former. 







L132 0.44±0.03 0.0143±0.0012 2.18±0.12 0.45±0.10 0.047±0.013 9.57±3.40 






Figure 3.2. Cytotoxicity curves of the L132 and A549 cell lines when treated with a Bcl-2 inhibitor (ABT-737). 
Curves were obtained by plotting the cell survival as a function of log(inhibitor concentration). Cell survival was 
determined by the colony assay, and data were fitted to a 4-parameter logistic equation (Eq. 2.3). Data points are 
means ± SEM of 3 independent experiments. The log of the concentration at which 50% of cells survive (logEC50) 
is that at which each survival curve intersects the horizontal dashed line (as indicated by the arrow heads). 
 
 
The observation that ABT-737 is more toxic in the normal than the cancer cells is also apparent 
from the inhibitor cytotoxicity parameters that are summarised in Table 3.2, with the L132 
requiring about 65% of the inhibitor concentration needed by the A549 for 50% cell kill. This 











Table 3.2: Summary of cytotoxicity data for the L132 and A549 cell lines treated with Bcl-2 inhibitor (ABT-
737). EC50 denotes the equivalent concentration for 50% cell survival. T and B are the maximum and minimum 
of the concentration-response curve, respectively (Figure 3.2). HS is the steepest slope of the curve (negative sign 
indicates a left to right decline in response with increasing concentration). 
 
 
3.3. Cytotoxicity of ABT-888 in L132 and A549 Cells 
 
When PARP-1 was inhibited by ABT-888, a concentration-dependent cytotoxic effect was also 
observed in both cell lines (Figure 3.3). As in the case of Bcl-2 inhibition, the normal cell line 
(L132) was more sensitive to PARP-1 inhibition than its cancer counterpart (A549). 
 
 
Figure 3.3. Cytotoxicity curves of the L132 and A549 cell lines when treated with a PARP-1 inhibitor (ABT-
888). Curves were obtained by plotting the cell survival as a function of log(inhibitor concentration). Cell survival 
Treatment Cell line EC50 (nM) T B HS 
ABT-737 
L132 5819±163 0.97±0.01 -0.002±0.001 -4.46±0.49 





was determined by the colony assay, and data were fitted to a 4-parameter logistic equation (Eq. 2.3). Data points 
are means ± SEM of 3 independent experiments. The log of the concentration at which 50% of cells survive 
(logEC50) is that at which each survival curve intersects the horizontal dashed line (as indicated by the arrow 
heads). 
 
The ABT-888 cytotoxicity parameters are listed in Table 3.3. The normal cell line requires 
only about 17% of the EC50 of the cancer cell line to reach a 50% cell death, indicating that use 
of ABT-888 alone might lead to extensive normal tissue toxicity. The high sensitivity of the 
L132 cell line to ABT-888 treatment is also clear from its cytotoxicity curve showing a ~2-fold 
slope relative to that of the A549 cell line.  
 
Table 3.3: Summary of cytotoxicity data for the L132 and A549 cell lines treated with PARP-1 inhibitor (ABT-
888). EC50 denotes the equivalent concentration for 50% cell survival. T and B are the maximum and minimum 
of the concentration-response curve, respectively (Figure 3.3). HS is the steepest slope of the curve (negative sign 
indicates a left to right decline in response with increasing concentration). 
 
 
3.4. Modulation of Radiation Response by Inhibitors 
 
To evaluate the effect of inhibition of Bcl-2 and PARP-1 with ABT-737 and ABT-888, 
respectively, on the radiation response of L132 and A549 cells, radiomodifying factors were 
estimated as described under Section 2.6 (Eq. 2.4). Single or concomitant inhibition of Bcl-2 
and PARP-1 in the normal cell line (L132) prior to a 2-Gy exposure resulted in an insignificant 
Treatment Cell line EC50 (nM) T B HS 
ABT-888 
L132 12.79±2.35 0.96±0.05 -0.027±0.055 -1.56±0.38 





radiosensitisation (Table 3.4; 0.22  P  0.56). Although the inhibition yielded up to a 2-fold 
radiosensitisation and corresponding modifying factors ranging from 2.05 to 3.40, the 
reduction in the radioresistance of L132 did not reach statistical significance. This is likely due 
to the large errors in surviving fraction, especially those for irradiation alone and pre-treatment 
with ABT-888. The surviving fractions following irradiation alone in the radiomodulation 
experiments (Table 3.4) were generally higher than those obtained in the preliminary intrinsic 
radiosensitivity experiments (Table 3.1), but the two data sets were comparable within the 
limits of experimental error.   
 
For the cancer cell line (A549), inhibition of Bcl-2 and PARP-1 (singly or in combination) 
consistently resulted in moderate to strong radiosensitisation, with modifying factors ranging 
from 1.52 to 5.30 (Table 3.4). Specifically, pre-treatment with ABT-737 alone or a combination 
of ABT-737 and ABT-888 yielded a significant reduction in cell survival of the order of 2.3 to 














Table 3.4. Modifying factors (MF), relative to X-ray treatment alone, derived from clonogenic survival at 2 Gy, 
for 2 human lung cell lines (normal: L132; cancer: A549) irradiated in the presence of ABT-737 and ABT-888.  
*Significant difference in cell survival, relative to survival at 2 Gy; #Errors calculated from a standard error 
propagation formula. 
 
Pre-treatment of the L132 cells with Bcl-2 and PARP-1 inhibitors (singly or concomitantly) 
before a 6-Gy irradiation resulted in a moderate (P  0.0556) to large (P  0.0315) reduction 
in cell survival, yielding modifying factors of 2.67 to 9.73 (Table 3.5). Similarly, pre-treatment 
of the cancer cell line with ABT-737 or ABT-888 led to significant radiosensitisation at 6 Gy, 
with modifying factors of 3.0 and 5.25, respectively (Table 3.5; P = 0.0141; P = 0.0242). A 
pre-irradiation treatment of A549 cells with a combination of ABT-737 and ABT-888 seemed 
to be too toxic and it was not possible to determine a surviving fraction, and a corresponding 
modifying factor. The addition of the inhibitors at a high dose of 6 Gy showed strong evidence 
against the null hypothesis, as significant radiosensitisation was observed in both cell lines, and 
could negatively impact on normal tissues. 
  
Cell line Treatment SF P-value MF# 
 
L132 
2 Gy 0.4935 ± 0.3035 - - 
ABT-737+2 Gy 0.2143 ± 0.0308   0.3111 2.30 ± 1.45    
ABT-888+2 Gy 0.2405 ± 0.2185   0.5685 2.05 ± 2.25    
ABT-737+ABT-888+2 Gy 0.1453 ± 0.0211 0.2240 3.40 ± 2.15 
 
A549 
2 Gy 0.5930 ± 0.0853 - - 
ABT-737+2 Gy 0.2597 ± 0.0177 0.0187* 2.28 ± 0.36 
ABT-888+2 Gy 0.3913 ± 0.0383  0.0973 1.52 ± 0.26 





Table 3.5. Modifying factors (MF), relative to X-ray treatment alone, derived from clonogenic survival at 6 Gy, 
for 2 human lung cell lines (normal: L132; cancer: A549) irradiated in the presence of ABT-737 and ABT-888. 
n.d. denotes parameters that could not be determined. 
*Significant difference in cell survival, relative to survival at 6 Gy; #Errors calculated from a standard error 
propagation formula; &error less than 0.0001 (actual error used in error propagation). 
 
 
Cell line Treatment SF P-value MF# 
 
L132 
6 Gy 0.1070 ± 0.0000& - - 
ABT-737+6 Gy 0.0401 ± 0.0250   0.0556 2.67 ± 1.66    
ABT-888+6 Gy 0.0110 ± 0.0001   <0.0001* 9.73 ± 0.09    
ABT-737+ABT-888+6 Gy 0.0262 ± 0.0249   0.0315* 4.08 ± 3.88 
 
A549 
6 Gy 0.0420 ± 0.0050 - - 
ABT-737+6 Gy 0.0140 ± 0.0031 0.0141* 3.00 ± 0.75 
ABT-888+6 Gy 0.0080 ± 0.0020  0.0242* 5.25 ± 1.45 




















Ionising irradiation as monotherapy has been tremendously explored together with surgery and 
chemotherapy in clinics as an alternative therapeutic mode for cancers (Hastak et al., 2017). 
However, no matter the therapeutic potential of radiotherapy, significant limitations have been 
recorded due to tumour resistance to treatment, cancer cell regrowth and normal tissue damage. 
To address this challenge, a novel therapeutic approach employing cocktails of biomolecules 
in combination with ionising irradiation was evaluated in this study, with the ultimate aim of 
identifying biomolecule mixtures that could radiosensitise cancer cells to radiotherapy. 
Specifically, the effect of inhibiting anti-apoptotic Bcl-2 protein with ABT-737 and the DNA 
repair protein, PARP-1, with ABT-888, singly or in combination, on cellular radiosensitivity 
was evaluated. Inhibitor-induced changes in radiosensitivity of two human cell lines (cancer: 
A549; apparently normal: L132) were assessed using the colony forming assay. Inhibitors were 
used at their respective concentrations for 50% cell inactivation. 
 
4.1. Intrinsic Cellular Radiosensitivity 
 
A preliminary assessment of the relative cellular radiosensitivity showed no apparent 
difference in the radiation response the cell lines at 2 Gy, but the apparently normal cell line 
(L132) emerged more radiosensitive than its malignant counterpart (A549) at a higher dose of 
6 Gy (Table 3.1). A similar trend in the radiosensitivity of these cell lines was previously 
observed (Hamid, 2019). However, the mean inactivation dose which accounts for the net 
cellular radiosensitivity over the entire dose range only showed that the cancer cells were 





significantly among the two cell types. The lack of a clear distinction in the radiosensitivity of 
the cell lines used here has also been demonstrated by other investigators (Verheye-Dua and 
Böhm, 1998; Hamid, 2019). This is also apparent in the absence of marked difference between 
the α/β ratios which are indicators of overall cell lethality in radiotherapy (Karagounis et al., 
2017). These findings cannot be corroborated by the report that the A549 highly expresses 
complement factor H (CFH) while the L132 does not (Yoon et al., 2019). Overexpression of 
CFH would lead to faster replication in the cancer cells compared to their normal counterparts, 
which should render the former cells more susceptible to radiation insult. In the clinical realm, 
genetic factors play a crucial role in the variation in tissue response to radiotherapy 
(Andreassen et al., 2002; Ho et al., 2006; Barnett et al., 2009; Tung et al., 2015). The level of 
expression of the DNA repair genes and the activity of the encoded proteins are determinants 
of radioresistance. That the radiosensitivities of these cell lines are comparable may be 
explained by the fact that they both have wild-type p53 (Takeyama et al., 2004; Berglind et al., 
2008), and should be expected to respond similarly to radiation-induced damage. The 
marginally higher radioresistance of the A549 cell line may be attributable to its 
downregulation of p53 expression (Reddy et al., 2020), which could potentially suppress p53-
mediated cell inactivation following radiation exposure.  
  
4.2. Cytotoxicity of ABT-737 and ABT-888 
 
Based on clonogenic cell survival, the cancer cell line (A549) emerged more resistant to Bcl-2 
inhibition with ABT-737 than its normal counterpart (L132), requiring ~55% more inhibitor 
for 50% cell inactivation than the latter (Figure 3.2; Table 3.2). The resistance to Bcl-2 
inhibition seen in the A549 cells is consistent with that reported elsewhere (Han et al., 2015; 





(Hamid, 2019). Although both are Bcl-2 inhibitiors, ABT-263 appeared to be more effective 
(molar per molar) than ABT-737. This was confirmed by the higher concentrations of ABT-
737 needed by both cell lines to reach 50% of the cell killing in the current study compared to 
those of Hamid (Hamid, 2019). It is conceivable that such relative resistance is due to 
expression of Bcl-2 in these cells (Han et al., 2015; Reddy et al., 2020). Higher levels of Bcl-2 
expression have been reported in normal lung tissue (Pezzella et al., 1993). This could act as a 
precursor for the sensitivity to Bcl-2 targeting observed in the apparently normal L132 cells, 
as high expression of Bcl-2 would be an indication of a high level of dependence of the cells 
on this anti-apoptotic gene for survival. The apparent resistance of the cancer cells (A549) to 
ABT-737 treatment might also be due the observation that the inhibitor is effective on Bcl-2 
and Bcl-xl, but not Mcl-1 (Yang et al., 2009). This may offer the malignant cells another anti-
apoptotic pathway of escape.  
 
A similar trend emerged when PARP-1 was inhibited with ABT-888, with the A549 cells 
requiring about 6-fold higher concentration of inhibitor to reach the 50% level of cell kill when 
compared with the apparently normal L132 cells (Figure 3.3; Table 3.3). This finding is in 
contrast with the report that the L132 cell line was more resistant to PARP-1 inhibition with a 
novel lipopeptide (Hajare et al., 2013). This inconsistency cannot be explained by differences 
in PARP-1 expression, as PARP-1 is minimally expressed in the cancer cell line, relative to its 
normal counterpart (Lee et al., 2013). The disparity in findings may be associated with factors 
such as an alteration of the drug target and heterogeneity in target cell population (Kvinnsland 
et al., 2001; Akudugu et al., 2011; Akudugu and Howell, 2012; Torres-Martinez et al., 2021). 
However, the cytotoxicity induced by ABT-888 in cell lines used here may be attributable to 





protein kinase B, extracellular signal-regulated kinases (ERK1/2), and p38-mediated EGFR 
pathways (Chowdhury et al., 2019). 
 
4.3. Radiomodulation by ABT-737 and ABT-888 
 
In this report, pre-treatment of the Bcl-2 and PARP-1 inhibitors followed by a 2-Gy irradiation 
yield modifying factors of statistical significance only in the cancer cell line (A549). This 
emerged when cells were treated with either ABT-737 alone or an ABT-737/ABT-888 cocktail 
prior to irradiation, where the A549 cells were radiosensitise by ~2- to 5-fold (Table 3.4). At a 
larger dose of 6 Gy, prior inhibitor treatment resulted in an even higher radiosensitisation of 
~4- to 10-fold in the apparently normal cell line (L132) for single ABT888 and ABT-737/ABT-
888 cocktail exposure (Table 3.5). A radiosensitisation of ~3- to 5-fold was observed in the 
A549 cells following pre-treatment with ABT-737 alone or an ABT-737/ABT-888 cocktail; 
and was comparable to that seen in the 2-Gy irradiation. 
 
The significant levels of radiosensitisation seen in the normal and malignant cell lines can be 
attributed to multiple factors that mediate the inherent sensitivity of the cells to the inhibitors. 
These include, but not limited to, the target expression profiles (Pezzella et al., 1993; Han et 
al., 2015; Reddy et al., 2020) and inactivation of non-targeted survival pathways (Chowdhury 
et al., 2019). Silencing of specific and non-specific targets by the inhibitors should be expected 
to render the cells more susceptible to radiation insult. The current findings, however, seem to 
indicate that use of these Bcl-2 and PARP-1 inhibitors may not be advisable in 
hypofractionated radiotherapy where large fractions of absorbed radiation doses are employed. 
This, as the apparently normal cells are radiosensitised to a much larger extent compared to 





fractional doses might exacerbate normal tissue effects. The findings appear to suggest that 
inhibition of Bcl-2 alone or a concomitant inhibition of Bcl-2 and PARP-1, when combined 

























This study demonstrates that both the apparently normal and malignant cell lines (L132 and 
A549, respectively) are highly radiosensitised when Bcl-2 and PARP-1 are inhibited at a large 
fractional dose of radiation. However, inhibition of Bcl-2 alone or combined inhibition of Bcl-
2 and PARP-1 at a lower dose of 2 Gy results in significant radiosensitisation in only the lung 
cancer cell line (A549). It can be suggested that inhibition of Bcl-2 and PARP-1 might be of 







Possible Future Avenues 
 
To fully elucidate the potential benefits of combining Bcl-2 and PARP-1 inhibition with 
radiotherapy, it would be of interest to explore the following avenues:  
1. Conduct in-depth studies on the mechanisms underlying the radiosensitisation 
exhibited by the Bcl-2 and PARP inhibitors, using techniques like western blotting, real 
time polymerase chain reactions, and flow cytometry.  
2. An expansion of the panel of cell lines (multiple normal and malignant cell lines) could 
shed more light on cell-type specific radiosensitisation by the inhibitors. 
3. Consideration of non-specific key parameters that may play a potential role in the 
explanation of the difference in radiosensitivity and alternative therapeutic modality of 
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